17-Alpha-Hydroxyprogesterone Caproate for the Prevention of Preterm Birth in Women With Prior Preterm Birth and a Short Cervical Length

被引:1
|
作者
Berghella, Vincenzo [1 ]
Figueroa, Dana
Szychowski, Jeff M.
Owen, John
Hankins, Gary D. V.
Iams, Jay D.
Sheffield, Jeanne S.
Perez-Delboy, Annette
Wing, Deborah A.
Guzman, Edwin R.
机构
[1] Thomas Jefferson Univ, Jefferson Med Coll, Dept Obstet & Gynecol, Div Maternal Fetal Med, Philadelphia, PA 19107 USA
关键词
D O I
10.1097/OGX.0b013e3181f07822
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
The primary risk factors for recurrent spontaneous preterm birth (SPTB) are a history of SPTB and a short cervical length (CL) found on second trimester transvaginal ultrasound (TVU). In women with prior SPTB or a short CL, the most frequently used interventions to prevent preterm birth (PTB) are cerclage and progesterone supplementation. It is unclear whether the effects of the progesterone agent 17-alpha-hydroxyprogesterone caproate (17P) are additive in women with both primary risk factors. It is also unclear whether 17P is beneficial for women with a prior SPTB and a short CL not undergoing TVU-indicated cerclage. The aim of this study was to evaluate the effect of 17P for the prevention of PTB in pregnant women with prior SPTB, and a short CL, with and without TVU-indicated cerclage. The study was a secondary analysis of a randomized controlled trial sponsored by the Eunice Kennedy Shriver National Institute of Child Health and Human Development, evaluating cerclage for singleton women with prior SPTB (17-33 6/7 weeks), and CL < 25 mm between 16 and 22 6/7 weeks. The trial was conducted by 15 US clinical centers from 2003 through 2007. The women available for the final analysis were randomized to cerclage (n = 148) or no cerclage (n = 152). The primary study outcome was the effect of 17P on PTB < 35 weeks' gestation. The cerclage and no-cerclage groups were analyzed separately. The data showed that 17P had no effect on PTB < 35 weeks in women with or without cerclage (P = 0.64; P = 0.51, respectively). The use of 17P in the no-cerclage group significantly lowered the odds of PTB < 24 weeks (odds ratio [OR], 0.08; P = 0.0022) and perinatal death (OR, 0.14; P = 0.0029). These findings suggest that the use of 17P in women with prior SPTB who underwent TVU-indicated cerclage for short CL < 25 mm provides no additive benefit for prevention of PTB < 35 weeks. In women with these primary risk factors who did not receive cerclage, 17P was associated with reduced previable birth and perinatal mortality.
引用
收藏
页码:477 / 478
页数:2
相关论文
共 50 条
  • [31] Does 17-alpha Hydroxyprogesterone Caproate Prevent Recurrent Preterm Birth in Obese Women?
    Eke, Ahizechukwu C.
    OBSTETRICS AND GYNECOLOGY, 2016, 128 (02): : 403 - 404
  • [32] Does 17-alpha hydroxyprogesterone caproate prevent recurrent preterm birth in obese women?
    Heyborne, Kent D.
    Allshouse, Amanda A.
    Carey, J. Christopher
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2015, 213 (06) : 844.e1 - 844.e6
  • [33] 17 α-Hydroxyprogesterone Caproate (Makena®) A Guide to Its Use in the Prevention of Preterm Birth
    Hines, Mary
    Lyseng-Williamson, Katherine A.
    Deeks, Emma D.
    CLINICAL DRUG INVESTIGATION, 2013, 33 (03) : 223 - 227
  • [34] 17-hydroxyprogesterone caproate for women with history of preterm birth in a prior pregnancy and twins in the current pregnancy
    Combs, C. Andrew
    Garite, Thomas J.
    Maurel, Kimberly
    Cebrik, Deborah
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2012, 206 (01) : S213 - S213
  • [35] Impact of prior gestational age at preterm delivery on effectiveness of 17-alpha-hydroxyprogesterone caproate in practice
    Gonzalez-Quintero, Victor H.
    de la Torre, Lesley
    Rhea, Debbie J.
    Tudela, Carmen M.
    Vazquez-Vera, Enrique
    Desch, Cheryl
    Istwan, Niki B.
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2010, 203 (03) : 257.e1 - 257.e5
  • [36] Utilization, adherence, and outcomes of 17-alpha hydroxyprogesterone caproate for recurrent spontaneous preterm birth prevention
    Zhang, Shiyu
    Rascati, Karen L.
    CURRENT MEDICAL RESEARCH AND OPINION, 2021, 37 (09) : 1667 - 1675
  • [37] Prevention of Preterm Birth in Triplets Using 17 Alpha-Hydroxyprogesterone Caproate A Randomized Controlled Trial
    Caritis, Steve N.
    Rouse, Dwight J.
    Peaceman, Alan M.
    Sciscione, Anthony
    Momirova, Valerija
    Spong, Catherine Y.
    Iams, Jay D.
    Wapner, Ronald J.
    Varner, Michael
    Carpenter, Marshall
    Lo, Julie
    Thorp, John
    Mercer, Brian M.
    Sorokin, Yoram
    Harper, Margaret
    Ramin, Susan
    Anderson, Garland
    OBSTETRICS AND GYNECOLOGY, 2009, 113 (02): : 285 - 292
  • [38] Preterm Birth Prevention by 17 Alpha-Hydroxyprogesterone Caproate vs. Daily Nursing Surveillance
    Rittenberg, Charles
    Newman, Roger B.
    Istwan, Niki B.
    Rhea, Debbie J.
    Stanziano, Gary J.
    JOURNAL OF REPRODUCTIVE MEDICINE, 2009, 54 (02) : 47 - 52
  • [39] Cerclage for the prevention of preterm birth in high risk women receiving intramuscular 17-α-hydroxyprogesterone caproate
    Szychowski, Jeff M.
    Berghella, Vincenzo
    Owen, John
    Hankins, Gary
    Iams, Jay D.
    Sheffield, Jeanne S.
    Perez-Delboy, Annette
    Wing, Deborah A.
    Guzman, Edwin R.
    JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE, 2012, 25 (12): : 2686 - 2689
  • [40] Effectiveness of 17-α-Hydroxyprogesterone Caproate on Preterm Birth Prevention in Women with History-Indicated Cerclage
    Mackeen, A. Dhanya
    Rafael, Timothy J.
    Zavodnick, Jillian
    Berghella, Vincenzo
    AMERICAN JOURNAL OF PERINATOLOGY, 2013, 30 (09) : 755 - 758